Roche has launched a Phase III study in collaboration with Gilead to evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) in combination with remdesivir in hospitalised patients with severe COVID-19 pneumonia.
Roche begins trial of Actemra/RoActemra plus remdesivir
No Comments
Previous Post
Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
Next Post
Pfizer, Germany’s BioNTech release new data on Covid-19 vaccine
Recent Posts
- Gilead’s cell therapy Yescarta awarded FDA approval for follicular lymphoma 08/03/2021
- FDA approval brings remote programming for Abbott’s deep brain stimulation device 08/03/2021
- Beckman Coulter seeks authorization for $4 antigen test 28/01/2021
- 3 tech-driven innovative patient engagement strategies transforming healthcare today 09/12/2020
- Lucira Covid-19 test is first to get FDA nod for home use 19/11/2020
Categories
- Coding (3)
- news (17)
- Photography (3)
- Social Marketing (3)
- uncategorized (1)
- WordPress (4)